Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
20 janv. 2021 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist...
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
12 nov. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
10 nov. 2020 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Company intends to shorten fully-enrolled Phase 3 dermatomyositis trial to 28 weeks from 52 weeks following recent developments in competitive landscape; data now expected as early as the second...
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
09 nov. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background...
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
03 nov. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Company to host conference call and webcast on Tuesday, November 10 at 8:30 a.m. ET Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
23 oct. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
As previously reported, lenabasum did not meet its primary efficacy endpoint in the studyLenabasum was well tolerated with no new safety findingsExploratory post-hoc analyses revealed unexpectedly low...
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
21 oct. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Preliminary baseline subject demographics and disease characteristics in a Phase 3 clinical trial of the safety and efficacy of lenabasum in dermatomyositis (DETERMINE)Cannabinoid receptor type 2...
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
08 oct. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Company is restructuring with the goal of extending cash runway to mid-2022Workforce to be reduced by 54%Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline...
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
06 oct. 2020 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Study did not meet primary endpoint of reducing rate of pulmonary exacerbationsLenabasum treatment had a favorable safety profile and was well-toleratedData to be presented at the upcoming North...
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
08 sept. 2020 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapyUnprecedented improvement was observed...